SalvaRx Group PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2011
2012
2013
2014
2015
Cash & Short Term Investments
50,930.00
39,531.00
26,792.00
1,341.00
908.00
Total Accounts Receivable
2,840.00
850.00
263.00
47.00
13.00
Other Current Assets
560.00
127.00
60.00
48.00
82.00
Total Current Assets
54,330.00
40,508.00
27,115.00
1,436.00
1,003.00
Total Investments and Advances
-
14,905.00
23,515.00
-
215.00
Other Assets
14,850.00
2,839.00
2,357.00
-
-
Total Assets
69,180.00
58,252.00
52,987.00
1,436.00
1,218.00
ST Debt & Current Portion LT Debt
1,165.00
-
-
-
-
Accounts Payable
1,150.00
235.00
178.00
83.00
77.00
Other Current Liabilities
4,673.00
1,324.00
245.00
61.00
45.00
Total Current Liabilities
6,988.00
1,559.00
423.00
144.00
122.00
Provision for Risks & Charges
528.00
-
-
-
-
Total Liabilities
7,516.00
1,559.00
423.00
144.00
122.00
Common Equity (Total)
61,664.00
56,693.00
52,564.00
1,292.00
1,096.00
Total Shareholders' Equity
61,664.00
56,693.00
52,564.00
1,292.00
1,096.00
Total Equity
61,664.00
56,693.00
52,564.00
1,292.00
1,096.00
Liabilities & Shareholders' Equity
69,180.00
58,252.00
52,987.00
1,436.00
1,218.00

About SalvaRx Group

View Profile
Address
Commerce House
Ramsey Isle of Man IM8 2LQ
United Kingdom
Employees -
Website http://www.salvarx.io
Updated 07/08/2019
SalvaRx Group Plc is a drug discovery and development company which focuses on immune-oncology. It invests in novel cancer immune-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies. The company was founded by Ian B.